Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.52 |
| ▸ | NOS2 | P35228 | 7/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746298 | 0.83 | NOS2 (0.48) | SLC6A2SLC6A4NOS2CYP2D6S1PR1 | |
| Hydrochloric Acid SCHEMBL6752544 | 0.82 | NOS2 (0.48) | SLC6A2SLC6A4NOS2CYP2D6S1PR1 | |
| SCHEMBL6746314 | 0.82 | NOS2 (0.52) | SLC6A2SLC6A4NOS2CYP2D6S1PR1 | |
| SCHEMBL6746312 | 0.82 | NOS2 (0.52) | SLC6A2SLC6A4NOS2CYP2D6S1PR1 | |
| SCHEMBL6187815 | 0.81 | SLC6A2 (0.46) | SLC6A2SLC6A4NOS2CYP2D6S1PR1 | |
| SCHEMBL6746335 | 0.79 | NOS2 (0.46) | SLC6A2SLC6A4NOS2CYP2D6S1PR1 | |
| SCHEMBL6748032 | 0.78 | NOS2 (0.55) | SLC6A2SLC6A4NOS2CYP2D6S1PR1 | |
| Hydrochloric Acid SCHEMBL6855347 | 0.78 | NOS2 (0.54) | SLC6A2SLC6A4NOS2CYP2D6S1PR1 | |
| Hydrochloric Acid SCHEMBL6855357 | 0.78 | NOS2 (0.54) | SLC6A2SLC6A4NOS2CYP2D6S1PR1 | |
| SCHEMBL6748057 | 0.74 | NOS2 (0.48) | SLC6A2SLC6A4NOS2CYP2D6S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572655-A2 | NOVEL ARYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | claimed |
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | claimed |
| WO-2002090332-A2 | NOVEL AEYLHETEROALKYLAMINΕ DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-14 | — | — | WO | claimed |
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | SLC6A2 2580/4885SLC6A4 1815/4885NOS2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.